Pyxis Oncology, Inc. (PYXS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Pyxis Oncology, Inc. (PYXS) closed at USD 1.80 on 2026-10-15, a change of -45.6 % over the past year, with a market capitalization of USD 200.69M.

Pyxis Oncology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Pyxis Oncology, Inc. key figures

Previous close

USD 1.80 (2026-10-15)

1-year change

-45.6 %

Market cap

USD 200.69M

Enterprise value

USD 124.96M

P/E ratio (trailing)

-1.20

P/E ratio (forward)

-1.52

EPS (trailing)

-1.40

EPS (forward)

-1.11

PEG ratio

n/a

Price to book

9.33

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.95

Employees

56

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Pyxis Oncology, Inc. and compare it with other stocks.